Researchers at the University of California at San Diego School of Medicine found that androgen deprivation therapy, regardless of duration, didn't have a significant association with the development of any dementia, vascular dementia or Alzheimer's disease among male veterans with nonmetastatic prostate cancer who underwent definitive radiotherapy. The findings of the observational cohort study were published in JAMA Oncology.
Study: ADT doesn't raise dementia risk in vets with prostate cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.